Information Provided By: 
Fly News Breaks for July 13, 2017
BMRN
Jul 13, 2017 | 06:47 EDT
Deutsche Bank analyst Andrew Peters says BioMarin remains one of his top-picks in the Biotech sector after hosting investor meetings in Europe with management. The analyst views the data for the company's hemophilia program as "quite strong." The data and decision to move forward with the high-dose cohort into Phase 3 trials is very positive and the subsequent stock reaction "does not appreciate the implications" of the hemophilia update, Peters tells investors in a research note. He reiterates a Buy rating on BioMarin with a $118 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN
